HK Stock Market Move | IMPACT THERAP-B (07630) fell over 13% in the afternoon, with a cumulative decline of nearly 70% since early July. The total market value is now less than HKD 3.5 billion.

IMPACT THERAP-B (07630) fell over 13% in afternoon trading, and as of the time of publication, it had dropped 12.47%, trading at HKD 11.58, with a transaction volume of HKD 5.2774 million. On the news front, on July 30, Eirena Pharmaceuticals announced that it has signed an exclusive licensing cooperation agreement with Pharmanova, granting it exclusive rights for the production, R&D, and commercialization of senaparib in Europe, the Middle East, North Africa, Australia, and New Zealand for maintenance monotherapy in patients with advanced high-grade epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Eirena Pharmaceuticals stands to gain a total of up to 423.5 million. It is worth noting that the market had previously widely predicted that, due to Eirena Pharmaceuticals meeting the market capitalization requirements for Hong Kong Stock Connect, it would be successfully included in the program in September 2026. Reports indicate that the assessment for the upcoming September adjustment of the Hong Kong Stock Connect is based on the market capitalization as of June 30. However, following the implementation of the assessment, the stock quickly plummeted, crashing 45% on July 2, and the share price continues to decline. As of August 3, the market capitalization has dropped to below HKD 3.5 billion.